Univariable Analysis of Acute GVHD
| . | Grade 2-4 . | . | P Value . |
|---|---|---|---|
| Matched | 16/80 | (20.0%) | .849 |
| Mismatched | 10/43 | (23.3%) | |
| HLA-C | |||
| Matched | 7/40 | (17.5%) | .627 |
| Mismatched | 8/32 | (25.0%) | |
| Matched | |||
| HLA-C matched | 7/34 | (20.6%) | .717 |
| HLA-C mismatched | 4/15 | (26.7%) | |
| HLA-C not tested | 5/31 | (16.1%) | |
| Mismatched | |||
| HLA-C matched | 0/6 | (0.0%) | .539 |
| HLA-C mismatched | 4/17 | (23.5%) | |
| HLA-C not tested | 6/20 | (30.0%) | |
| No methotrexate | 20/86 | (23.3%) | .525 |
| Methotrexate | 6/37 | (16.2%) | |
| Matched | |||
| No methotrexate | 16/74 | (21.6%) | .340 |
| Methotrexate | 0/6 | (0.0%) | |
| Mismatched | |||
| No methotrexate | 4/12 | (33.3%) | .427 |
| Methotrexate | 6/31 | (19.4%) | |
| Disease status | |||
| CR1 | 6/21 | (28.6%) | .529 |
| CR2 | 15/82 | (18.3%) | |
| CR3/CR4/relapse | 5/20 | (25.0%) | |
| CMV status | |||
| Neg/neg | 13/68 | (19.1%) | .698 |
| Any other | 13/55 | (23.4%) | |
| Donor gender3-150 | |||
| Male | 13/62 | (21.0%) | .925 |
| Female | 13/60 | (21.7%) | |
| HLA methodology | |||
| Pre-SSP | 7/36 | (19.4%) | .958 |
| SSP | 19/87 | (21.8%) |
| . | Grade 2-4 . | . | P Value . |
|---|---|---|---|
| Matched | 16/80 | (20.0%) | .849 |
| Mismatched | 10/43 | (23.3%) | |
| HLA-C | |||
| Matched | 7/40 | (17.5%) | .627 |
| Mismatched | 8/32 | (25.0%) | |
| Matched | |||
| HLA-C matched | 7/34 | (20.6%) | .717 |
| HLA-C mismatched | 4/15 | (26.7%) | |
| HLA-C not tested | 5/31 | (16.1%) | |
| Mismatched | |||
| HLA-C matched | 0/6 | (0.0%) | .539 |
| HLA-C mismatched | 4/17 | (23.5%) | |
| HLA-C not tested | 6/20 | (30.0%) | |
| No methotrexate | 20/86 | (23.3%) | .525 |
| Methotrexate | 6/37 | (16.2%) | |
| Matched | |||
| No methotrexate | 16/74 | (21.6%) | .340 |
| Methotrexate | 0/6 | (0.0%) | |
| Mismatched | |||
| No methotrexate | 4/12 | (33.3%) | .427 |
| Methotrexate | 6/31 | (19.4%) | |
| Disease status | |||
| CR1 | 6/21 | (28.6%) | .529 |
| CR2 | 15/82 | (18.3%) | |
| CR3/CR4/relapse | 5/20 | (25.0%) | |
| CMV status | |||
| Neg/neg | 13/68 | (19.1%) | .698 |
| Any other | 13/55 | (23.4%) | |
| Donor gender3-150 | |||
| Male | 13/62 | (21.0%) | .925 |
| Female | 13/60 | (21.7%) | |
| HLA methodology | |||
| Pre-SSP | 7/36 | (19.4%) | .958 |
| SSP | 19/87 | (21.8%) |
1 donor gender unknown.